SiBionics Explores New Horizons in Automated Insulin Delivery at EASD 2026
SiBionics presented "See More, Act Earlier" at the EASD 2026 Congress, merging continuous monitoring technology with future diabetes treatment approaches.
Milan, October 4, 2026 /PRNewswire/ -- SiBionics, a company focused on diabetes technology, showcased advancements in automated insulin delivery at the European Association for the Study of Diabetes (EASD) 2026 Congress. The company's presentation, titled "See More, Act Earlier," highlighted the integration of continuous glucose monitoring (CGM) technology with future diabetes care strategies.
The presentation emphasized how continuous monitoring can facilitate the prediction and prevention of significant glycemic fluctuations, a critical aspect of diabetes management. SiBionics' technology enables real-time data collection and analysis, supporting more precise and personalized treatment decisions.
The EASD Congress served as a forum for industry experts to discuss evolving trends in diabetes treatment. SiBionics' contribution demonstrated the potential for combining technological innovation with clinical insights to improve patient outcomes and reduce the risk of severe complications.
The company stated its ongoing commitment to research and development aimed at enhancing diabetes management through technological advancements, with the goal of providing more effective tools for both healthcare professionals and individuals managing diabetes.